Shelf life (days): 1460.0
Formulation: A solid
Formal Name: N-[4-[[6-amino-5-[(methoxyimino)methyl]-4-pyrimidinyl]oxy]-2-chlorophenyl]-N'-ethyl-urea
Purity: ≥98%
Formula Markup: C15H17ClN6O3
Formula Weight: 364.8
CAS Number: 951151-97-6
Notes: JNJ-38158471 is an inhibitor of VEGFR2 (IC50 = 42 nM).{68891} It is selective for VEGFR2 over the PDGFR family kinases CSF-1 receptor tyrosine kinase (FMS), PDGFRα, FMS-related tyrosine kinase 3 (FLT3), and KIT (IC50s = 624, 1,109, 4,810, and 511 nM, respectively) and VEGFR family kinases VEGFR1 and VEGFR3 (IC50s = 4,451 and 1,112 nM, respectively) but does inhibit RET (IC50 = 183 nM). JNJ-38158471 (10, 100, or 500 nM) decreases VEGF-induced phosphorylation of VEGFR2 in serum-starved human umbilical vein endothelial cells (HUVECs). It inhibits VEGF-induced migration in HUVECs when used at a concentration of 1 µM. JNJ-38158471 (100 mg/kg) reduces Vegf-induced corneal neovascularization in mice. It decreases tumor size in an HCT116 colorectal cancer mouse xenograft model when administered at doses ranging from 10 to 200 mg/kg per day. JNJ-38158471 (100 mg/kg per day) reduces polyp number in an Apc+/Min-FCCC mouse model of spontaneous colorectal adenoma.
English
Deutsch
